To advance personalized cancer therapy, Owkin’s MOSAIC project is building the largest spatial multiomics dataset in oncology. The goal: to train AI models that detect disease subtypes, uncover biomarkers, and guide treatment decisions. The foundation of this endeavor is high-resolution molecular data from 7,000 tumor samples across seven cancer types – connecting cancer cells and their microenvironment. That is where CeGaT comes in: as the project’s European sequencing partner, we generate the high-resolution molecular data that powers the MOSAIC project.
Our role: high-resolution sequencing and smart data analysis
We receive tumor samples from four of the five participating clinical centers. Each sample undergoes a full set of sequencing analyses:
Figure 1 | Four sequencing approaches in MOSAIC.
Beyond sample processing, we perform secondary bioinformatic analyses, including sequencing quality control, alignment, variant calling, and annotation. Our in-house workflows are optimized for reproducibility, scalability, and consistent data quality across all modalities.
Designed for scale – with reliable, high-quality performance
Owkin launched the project in January 2024. With over 2,000 samples already processed, we have managed high volumes with consistent performance. The first results are already becoming visible: MOSAIC has recently launched its online ‘MOSAIC Window’ – offering researchers a first glimpse into the insights this project could deliver. These early insights are built on a robust sequencing framework that ensures consistency, reproducibility, and data quality across thousands of samples. To meet the project’s demanding requirements, we adapted our workflows – including setting up an additional version of our single-cell RNA sequencing product– to ensure reliable quality and efficiency at scale.
Enabling complex research – with depth and infrastructure
With extensive experience in research, CeGaT supports multiomics projects of all sizes. In MOSAIC, we contribute more than data – we provide the expertise, infrastructure, and flexibility required for successful execution.
We are proud to be part of this groundbreaking initiative – helping shape the future of personalized cancer care with high-quality sequencing.
